LLY Stock Recent News
LLY LATEST HEADLINES
INDIANAPOLIS and WEST LAFAYETTE, Ind. , May 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million in the collaboration over the next eight years.
Market volatility and near-term uncertainty can be challenging to deal with these days -- or at any time. However, even in the current environment, there are excellent investment opportunities.
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
With the second quarter of 2025 now over a month old, many investment funds will soon begin disclosing what stocks they held at the end of the first quarter, essentially providing investors a glimpse of what they bought and sold. It's a particularly interesting time to see how large institutional funds invested early in the year, given all of the volatility.
U.S. equities advanced at midday as President Donald Trump announced a new trade deal with the United Kingdom. The Dow Jones Industrial Average, S&P 500, and Nasdaq all rose.
There is plenty of movement in equity markets during earnings season, but from a fundamental standpoint, investment theses seldom change. That's why significant price drops in shares of quality businesses can be excellent buying opportunities.
INDIANAPOLIS , May 8, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced executive leadership transitions that will further enhance the company's ability to drive sustained, long-term growth and ensure that its medicines continue to reach millions of people worldwide. Lilly has experienced significant growth over the past several years, particularly in the U.S. and cardiometabolic health businesses.
For a while, it seemed as if Eli Lilly (LLY 0.21%) could do no wrong. Its shares skyrocketed.
A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly's blockbuster weight loss and diabetes drugs Zepbound and Mounjaro off a list of medicines in short supply, a ruling that could dash patients' hopes of regaining access to cheaper copies of the popular therapies.
Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.